Arrowhead Research
ARWR
$70.82
-5.82%
Arrowhead Pharmaceuticals Inc. is an American biotechnology company focused on developing medicines to treat genetically-driven diseases characterized by the overproduction of specific proteins. The company is a recognized player in the RNA interference (RNAi) therapeutic space, leveraging its proprietary Targeted RNAi Molecule (TRiM™) platform to create novel drugs targeting conditions in the liver, cardiovascular, pulmonary, and central nervous systems. The current investor narrative is heavily centered on the company's transition from a research platform to a commercial-stage entity, driven by promising clinical data for its lead liver disease candidates and recent strategic partnerships that validate its technology, though debates persist around the path to profitability and competitive intensity in the gene-silencing field.…
ARWR
Arrowhead Research
$70.82
Related headlines
Investment Opinion: Should I buy ARWR Today?
Rating: Hold. The core thesis is that ARWR is a high-potential but high-risk clinical-stage biotech where the current valuation fairly balances transformative growth prospects against binary clinical and execution risks.
Supporting Evidence: The stock's 5.56x trailing PS ratio is at a historical low for the company, suggesting a valuation reset. However, the forward EV/Sales of 17.24x remains demanding. Revenue growth is explosive at 104.61% YoY, but from a volatile, milestone-driven base. Profitability is inconsistent, with a trailing net margin of -0.2%. The company's strong liquidity (4.86 current ratio) and positive TTM FCF of $322M provide a crucial runway. Analyst sentiment is cautiously optimistic but based on limited coverage, offering no clear consensus price target for implied upside calculation.
Risks & Conditions: The two biggest risks are clinical trial failure leading to valuation collapse, and an inability to convert milestone payments into sustainable, recurring revenue. This Hold rating would upgrade to a Buy if the company demonstrates consistent quarterly profitability, secures a major new partnership, or the stock price corrects meaningfully below $60 (offering a larger margin of safety). It would downgrade to a Sell if TTM free cash flow turns negative, a key clinical trial misses its endpoint, or revenue growth decelerates sharply in the next two quarters. Based on the current data, the stock appears fairly valued relative to its own volatile history but richly valued on forward sales expectations, placing it in a 'show me' phase.
Sign up to view all
ARWR 12-Month Price Forecast
The outlook for ARWR is bifurcated, with the path forward heavily dependent on clinical execution and the conversion of its platform into sustainable revenue. The base case (50% probability) of consolidation between $65 and $85 is most likely, as the market digests recent gains and awaits concrete pipeline developments. The bull case offers significant upside but requires flawless execution, while the bear case presents severe downside risk inherent in the biotech model. The stance is neutral due to the balanced risk/reward at current prices; the stock is not cheap enough for deep value investors nor stable enough for conservative growth investors. An upgrade to bullish would require evidence of recurring revenue generation and a de-risking of the clinical pipeline. A downgrade to bearish would be triggered by a clinical failure or a breakdown below key technical support near $55.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Arrowhead Research's 12-month outlook, with a consensus price target around $92.07 and implied upside of +30.0% versus the current price.
Average Target
$92.07
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$57 - $92
Analyst target range
Analyst coverage for ARWR appears limited, with data indicating only 5 analysts providing estimates. The consensus sentiment leans bullish, as evidenced by recent institutional ratings from firms like HC Wainwright & Co., B. Riley Securities, and Piper Sandler maintaining "Buy" or "Overweight" ratings. However, the absence of a stated consensus price target in the provided data implies insufficient or fragmented coverage to derive a clear average target and implied upside/downside from the current $77.91 price.
The estimated revenue range for the forward period is wide, from a low of ~$1.00B to a high of ~$2.35B, with an average of ~$1.59B. This wide dispersion signals high uncertainty and a lack of strong consensus on the commercial potential and timing of key catalysts. The pattern of recent ratings shows stability (reiterations) rather than widespread upgrades or downgrades, suggesting analysts are in a 'wait-and-see' mode for clinical data readouts. Limited coverage is typical for mid-cap biotechs and can lead to higher volatility and less efficient price discovery, placing a greater onus on investors to conduct deep due diligence on the pipeline.
Bulls vs Bears: ARWR Investment Factors
The bull case, currently supported by stronger evidence, is anchored in the company's transformative revenue growth, strong balance sheet, and powerful technical momentum, suggesting a successful transition from platform to product. The bear case centers on the extreme volatility of earnings, a premium forward valuation, and the binary risk inherent in clinical-stage biotech. The single most important tension in the investment debate is whether the recent surge in milestone-driven revenue represents a sustainable inflection point towards commercial profitability, or merely a temporary spike before a return to heavy R&D burn. The resolution of this tension—through consistent future revenue generation from partnerships or product sales—will determine if the current valuation is justified or precarious.
Bullish
- Explosive Revenue Growth & Milestone Validation: Q1 2026 revenue surged 104.61% YoY to $264.03M, driven by significant milestone payments. This validates the company's TRiM™ platform and partnership strategy, demonstrating tangible progress towards commercialization.
- Strong Financial Position & Cash Flow: The company boasts a robust current ratio of 4.86 and generated $322.01M in trailing twelve-month free cash flow. This provides ample liquidity to fund expensive clinical trials without immediate dilution risk, a key advantage for a clinical-stage biotech.
- Powerful Technical Momentum & Relative Strength: The stock is up 363.20% over the past year and trades at 95% of its 52-week high ($82.26), showing strong bullish conviction. It has consistently outperformed the S&P 500, with a 12.86% relative strength over the past three months.
- Valuation Reset to More Reasonable Level: The trailing Price-to-Sales ratio of 5.56x is near the low end of its own historical range (which peaked at 938.86x), suggesting a valuation reset. This offers a more grounded entry point if the company can sustain its recent revenue trajectory.
Bearish
- Extreme Earnings Volatility & Unprofitability: Profitability is wildly inconsistent, swinging from a $175.24M net loss in Q3 2025 to a $30.81M profit in Q1 2026. Trailing EPS remains negative at -$0.00035, highlighting the binary, milestone-dependent nature of current earnings.
- High Valuation on Forward Metrics: The forward EV/Sales ratio is 17.24x, a premium multiple that prices in flawless execution of the pipeline. This leaves the stock vulnerable to significant multiple compression if revenue growth falters or clinical data disappoints.
- Limited Analyst Coverage & High Uncertainty: With only 5 analysts, price discovery is less efficient, contributing to volatility. The wide estimated revenue range ($1.00B to $2.35B) signals a severe lack of consensus on the commercial potential and timing of key catalysts.
- Technically Overextended Near All-Time High: Trading at $77.91, just 5% below its 52-week high of $82.26, the stock is vulnerable to a technical pullback and profit-taking. The 1-month gain of 10.46% also shows deceleration from the explosive longer-term trend, suggesting momentum may be peaking.
ARWR Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 363.20% gain over the past year. With a current price of $77.91, it is trading near the top of its 52-week range ($14.30 to $82.26), specifically at approximately 95% of that range, indicating strong momentum but also potential overextension and vulnerability to profit-taking near the all-time high. Recent momentum remains robust but shows signs of consolidation; the stock is up 10.46% over the past month and 23.14% over the past three months, both figures significantly outpacing the broader market (SPY up 6.31% and 10.28%, respectively), yet the 1-month gain is a deceleration from the explosive longer-term trend, suggesting a potential pause or digestion phase after the massive rally.
Key technical support is anchored at the 52-week low of $14.30, though more immediate support likely resides near recent consolidation zones around $55-$60, as seen in March 2026. The primary resistance is the 52-week high of $82.26; a decisive breakout above this level could signal a continuation of the bull run, while a failure and reversal could indicate a double-top formation. The stock exhibits high volatility with a beta of 1.289, meaning it is approximately 29% more volatile than the S&P 500, which is typical for a clinical-stage biotech and necessitates larger position-sizing buffers for risk management.
Beta
1.29
1.29x market volatility
Max Drawdown
-24.6%
Largest decline past year
52-Week Range
$14-$82
Price range past year
Annual Return
+331.8%
Cumulative gain past year
| Period | ARWR Return | S&P 500 |
|---|---|---|
| 1m | -5.3% | +5.4% |
| 3m | +8.8% | +10.9% |
| 6m | +9.5% | +11.0% |
| 1y | +331.8% | +28.1% |
| ytd | +4.5% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ARWR Fundamental Analysis
Revenue growth is highly volatile and lumpy due to the nature of partnership milestones, but the most recent quarter shows a dramatic positive inflection. For Q1 2026 (ending Dec 31, 2025), revenue surged to $264.03 million, representing a year-over-year growth of 104.61%. This follows a starkly negative trend in prior quarters, such as Q3 2025 revenue of only $27.77 million, indicating that growth is currently being driven by significant milestone payments rather than recurring product sales, which is characteristic of the biotech business model.
Profitability remains inconsistent. The latest quarter showed a net income of $30.81 million with a net margin of 11.67%, a sharp reversal from a net loss of $175.24 million in Q3 2025. Gross margin was 100% in the most recent quarter, typical for a company recognizing collaboration revenue. The operating margin was 15.46% for Q1 2026, compared to deeply negative operating margins in preceding quarters (e.g., -596.21% in Q3 2025), highlighting the extreme quarter-to-quarter variability driven by milestone recognition versus heavy R&D burn.
The balance sheet appears healthy with a strong current ratio of 4.86, indicating ample liquidity. Debt levels are moderate with a debt-to-equity ratio of 0.79. Critically, the company is generating substantial cash flow from operations in its profitable quarters; trailing twelve-month free cash flow is reported at $322.01 million. This strong FCF, coupled with a market cap of approximately $4.61 billion, suggests the company currently has the financial flexibility to fund its costly clinical development internally, reducing near-term dilution risk.
Quarterly Revenue
$264033000.0B
2025-12
Revenue YoY Growth
+104.61%
YoY Comparison
Gross Margin
+1.00%
Latest Quarter
Free Cash Flow
$322007000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ARWR Overvalued?
Given the company's inconsistent profitability (net income was positive $30.81M last quarter but trailing EPS is -$0.00035), the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 5.56x, while the forward-looking valuation is implied by an EV/Sales of 17.24x, indicating the market is pricing in significant future revenue growth and potentially the monetization of its clinical pipeline.
Comparing to industry averages is challenging with the provided data, but the stock's valuation is inherently speculative and tied to clinical outcomes rather than current financials. A PS ratio of 5.56x for a biotech with a validated platform and late-stage assets could be considered reasonable or even discounted if future sales projections from the analyst data (average estimated revenue of ~$1.59B) are credible, implying a forward PS of less than 3x based on current market cap.
Historically, the stock's own PS ratio has been extremely volatile, ranging from as high as 938.86x in Q1 2025 (during a period of minimal revenue) to a recent 5.56x. The current PS of 5.56x is near the lower end of its own historical spectrum over the past few years, suggesting the market may be applying a more conservative multiple to current revenues, or that the recent revenue surge has mechanically compressed the ratio. This could indicate a valuation reset that offers a more grounded entry point if the growth trajectory is sustainable.
PE
-2828.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -71x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is extreme earnings volatility, as net income swung from a $175M loss to a $31M profit in consecutive quarters, driven entirely by non-recurring milestone payments. This creates an unpredictable cash flow profile. While the balance sheet is currently strong with a 4.86 current ratio and $322M in TTM FCF, the company's business model requires sustained heavy R&D investment; a prolonged period without major partnership milestones could rapidly deplete cash reserves. Revenue concentration in lump-sum payments, rather than recurring product sales, adds significant operational risk to forecasting and valuation.
Market & Competitive Risks: The stock trades at a forward EV/Sales of 17.24x, a premium valuation that embeds high expectations for future growth. This makes it highly susceptible to valuation compression in a rising interest rate environment or if sector sentiment sours on high-growth, unprofitable biotech. Competitive intensity in the RNAi and gene-silencing space is fierce, with larger players like Alnylam and CRISPR Therapeutics (as noted in recent news) advancing rival therapies. ARWR's beta of 1.289 indicates it is 29% more volatile than the market, amplifying downside moves during broad market sell-offs.
Worst-Case Scenario: The worst-case scenario involves a critical clinical failure for a lead pipeline candidate, triggering a cascade of partnership renegotiations, analyst downgrades, and a loss of investor confidence in the TRiM™ platform. This could lead to a rapid unwind of the premium valuation and a retreat towards the stock's 52-week low of $14.30. A realistic downside from the current price of $77.91 in such an adverse scenario could be a decline of 60-80%, potentially breaching the $20 level, as the market reprices the company based on its cash balance and early-stage pipeline alone, absent near-term commercial prospects.
FAQ
The key risks are: 1) Clinical & Regulatory Risk: The entire value depends on successful trial outcomes and FDA approvals; a failure could crater the stock. 2) Financial Model Risk: Revenue and earnings are wildly volatile, swinging from deep losses to profits quarter-to-quarter based on milestone payments (e.g., Q3 2025 net loss of -$175M vs. Q1 2026 profit of $31M). 3) Valuation Risk: Trading at a forward EV/Sales of 17.24x, the stock is vulnerable to multiple compression if growth expectations are not met. 4) Competitive & Market Risk: Intense competition in RNAi therapeutics and a high beta of 1.29 make the stock prone to sharp declines in sector-wide sell-offs.
The 12-month forecast is highly scenario-dependent. The base case (50% probability) sees the stock consolidating between $65 and $85, as the company executes its clinical plans and recognizes expected partnership revenue. The bull case (25% probability) could drive the stock to $95-$120 on positive clinical data and new partnerships. The bear case (25% probability) could see a decline to $30-$55 on clinical setbacks or partnership issues. The base case is most likely, assuming no major binary events, but the wide range reflects the inherent uncertainty of a clinical-stage biotech. The key assumption is that the company continues to hit its development milestones without major surprises.
ARWR's valuation presents a mixed picture. On a trailing Price-to-Sales basis at 5.56x, it appears reasonably valued, especially compared to its own historical PS ratio which has exceeded 900x. However, the forward-looking EV/Sales ratio of 17.24x is premium, indicating the market is pricing in massive future revenue growth from its pipeline. Compared to profitable, commercial-stage biotech peers, ARWR is expensive. The valuation is not clearly overvalued or undervalued; it is fairly valued for its current stage but richly valued for its hoped-for future, making it highly sensitive to clinical news flow.
ARWR is a speculative buy only for investors with a high risk tolerance and a long-term investment horizon. The stock offers significant upside potential (analyst revenue estimates average ~$1.59B) if its clinical pipeline succeeds, but carries substantial downside risk, with a realistic bear-case target in the $30-$55 range. The current valuation (17.24x EV/Sales) prices in near-perfect execution, leaving little margin for error. It could be a good buy for a diversified, aggressive growth portfolio seeking biotech exposure, but investors must be prepared for volatility and have conviction in the company's TRiM™ platform.
ARWR is unequivocally a long-term investment, requiring a minimum horizon of 3-5 years to allow its clinical pipeline to mature and potentially generate commercial revenue. The stock's high volatility (beta 1.289), lack of dividends, and dependence on binary clinical outcomes make it poorly suited for short-term trading or income investors. Long-term investors can potentially ride out the volatility for transformative returns if the platform succeeds. Short-term traders would be exposed to extreme price swings on rumor, data leaks, and quarterly earnings surprises driven by non-recurring milestones.